In-use product safety report on dexamfetamine tablets for attention deficit hyperactivity disorder

A UKMi Product Safety assessment on dexamfetamine sulfate tablets for attention deficit hyperactivity disorder; in-use medication safety considerations resultant from the product presentation or other pre-defined characteristics are described. Potential next steps and mitigation actions are suggested.

UKMi Product Safety assessments are produced using the validated UKMi product assessment tool.

The UKMI product safety assessment group would appreciate your views on the usefulness of this assessment. We have devised a short survey which we would appreciate you completing, it should take approximately 10 minutes to complete. Click here – – to complete the survey.

DexamfetamineMedicines SafetyMental HealthMental health and illnessPaediatric and neonatal medicinePrimary CareTransfer of care